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HRQoL Measure
Baseline
(BL) 1 Mo
p value
(1 Mo
vs BL)
6
Mos
p value
(6 Mos
vs BL)
EQ-5D Summary
Index
0.62 0.72 0.001 0.72 0.001
SF12-PCS† 32.82 39.00 0.001 39.74 0.001
SF12-MCS† 46.18 48.51 0.001 49.98 0.001
EQ-5D: from 0 [death] to 1 [perfect health].
†SF-12: from 0 to 100, with a higher score reflecting a better HRQoL
Conclusions: The ADVANCE study represents the largest, rigorously reported cohort of
HRQoL findings in the TAVI literature. All HRQoL measures significantly improved
compared with baseline at 1 and 6 months. An assessment of HRQoL by patient risk
profile according to EuroSCORE will be presented at the meeting.
TCT-815
Prognostic Role Of Serum Cardiac Biomarker Elevation After Transcatheter
Aortic Valve Replacement
Israel Barbash1, Danny Dvir2, Itsik Ben Dor1, Salem Badr1, Petros Okubagzi1,
Rebecca Torguson2, Paul Corso3, Lowell Satler4, Augusto Pichard5,
Ron Waksman6
1Washington Hospital Center, Washington, DC, 2Washington Hospital center,
washington, DC, 3Washington Hospital center, Washington, DC, 4Washington
hospital center, washington, DC, 5washsington hospital center, Washington, USA,
6Georgtown University, Washington, DC
Background: The majority of patients have significant elevations in serum cardiac
biomarkers after transcatheter aortic valve replacement (TAVR) however the prognostic
significance of such elevations is unknown. Our aim was to assess incidence and
prognostic power of biomarker elevations after TAVR.
Methods: Clinical data of patients with aortic stenosis who were subjected to TAVR was
retrospectively analyzed. Myocardial necrosis markers cardiac troponin I (cTnI) and
creatine kinase (CK)-MB] were assessed during hospitalization.
Results: Among 150 TAVR patients, TA patients had significantly higher elevations both
for cTnI (13.814.0 vs. 2.55.8, p 0.001) and CK-MB (28.424.2 vs. 7.48.6, p
0.001) compared with TF patients. Biomarker elevations in TA patients did not have
any predictive power for patient outcome. However, by receiver operator curve analysis,
for TF patients, post-procedural CK-MB (2-fold increase) had high predictive power for
30-day mortality (area under the curve 0.85, p 0.001). Patients with high CK-MB had
higher rates of post-procedural kidney injury (22% vs. 6%, p0.026), in-hospital- (22%
vs. 0%, p 0.001), 30-day- (27% vs. 1.5%, p 0.001), and 1-year mortality (41% vs.
18%, p0.01).
Conclusions: Cardiac biomarker rise post-TAVR is common and more frequent among
TA access patients. A 2-fold increase (7 ng/ml) in CK-MB after TF-TAVR is a
surrogate for poor long-term outcome.
TCT-816
Anticipated Utilization of Transcatheter Aortic Valve Replacement Reflects
Cautious Optimism of the U.S. Interventional Cardiology Community
Akshar Patel1, Paul Hauptman1, Michael Lim1, Joshua Stolker1
1Saint Louis University, Saint Louis, MO
Background: Transcatheter aortic valve replacement (TAVR) is the first major addition
to the treatment of valvular heart disease in more than a decade, and the number of
patients eligible for valve replacement is likely to increase significantly. As a conse-
quence, little is known about expectations within the cardiology community regarding the
utilization of this new therapy in clinical practice.
Methods: Four days after approval of the first TAVR device in November 2011 by the
U.S. Food and Drug Administration (FDA), we emailed an online questionnaire to 201
cardiologists involved in TAVR research and 461 recent members of the Society of
Cardiac Angiography and Interventions to evaluate anticipated TAVR referral patterns.
Follow-up reminders were sent during the next 4 weeks. Characteristics between
researchers and clinicians were compared using chi-square and t-tests.
Results: Of 205 responses received (31%), the majority of respondents were male (90%),
interventional cardiologists (86%), and working in academic practices (72%). Most
respondents (90%) planned to refer patients for TAVR immediately after the devices are
clinically available, and 70% stated that no more data were needed to confirm TAVR is
safe for clinical use. Although 75% of respondents anticipated referring less than
one-fourth of their patients with severe aortic stenosis for TAVR, 68% believed that
TAVR is equally efficacious as open-heart surgery, and 11% believed that moderate-
surgical risk patients should also be referred for TAVR. When comparing groups of
respondents, those involved in TAVR research studies were more conservative with
regard to anticipated referral patterns, as 81% would refer as soon as TAVR is clinically
available versus 98% of clinical cardiologists (p0.01).
Conclusions: These data provide insight into the expected utilization of TAVR after
FDA approval in November 2011. Despite remarkable enthusiasm and media attention for
TAVR over the past few years, our findings suggest cautious optimism among the U.S.
interventional cardiology community regarding the uptake of this new approach to
managing severe aortic stenosis.
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Transcatheter Aortic Valve Replacement with a New Balloon Expandable
Percutaneous Heart Valve
Ronald Binder1, Josep Rodes-Cabau2, David Wood1, Michael Mok2,
Jonathon Leipsic1, Robert De Larochelliere2, Stefan Toggweiler1, Eric Dumont2,
Melanie Freeman1, Alex Willson1, John Webb1
1St. Paul’s Hospital - University of British Columbia, Vancouver, Canada,
2Quebec Heart and Lung Institute, Laval University, Quebec, Canada
Background: The SAPIEN 3 transcatheter heart valve (Edwards Lifesciences Inc., USA)
incorporates an enhanced paravalvular sealing system, an active 3-dimensional coaxial
positioning catheter, and is compatible with an ultra-low profile 14 French expandable
sheath.
Methods: As a first-in-human trial the SAPIEN 3 transcatheter heart valve (Edwards
Lifesciences Inc., CA, USA) was implanted in 15 patients with symptomatic severe aortic
stenosis via femoral arterial access with a 14 French expandable sheath. Patients
underwent transthoracic echocardiography and multidetector computed tomography both
before and after valve implantation. Clinical and echocardiographic follow up was
obtained at 30 days. Outcomes were reported according to the Valve Academic Research
Consortium guidelines.
Results: All 15 device implants were successful. Aortic valve area increased from 0.7
0.2 cm2 to 1.5 0.2 cm2 (p 0.001) and mean trans-aortic gradient decreased from
42.2  10.3 mmHg to 11.9  5.3 mmHg (p  0.001). No patient had more than mild
paravalvular regurgitation. Hospital discharge occurred at 3 (2, 12) hospital days. At
30 days one patient had required a new pacemaker. There were no strokes, vascular
complications, transfusions, or deaths. All patients were in NYHA functional class I
or II at 30-day follow-up.
Conclusions: The ultra-low SAPIEN 3 transcatheter valve and delivery system may
facilitate fully percutaneous implantation in a broader range of patients with the potential
for more accurate positioning and less paravalvular regurgitation.
TCT-818
Balloon Aortic Valvuloplasty In Severe Aortic Stenosis And Prevention Of
Restenosis In Elderly
Polonca Kogoj1, Špela Mušicˇ1, Nikola Lakicˇ1, Jana Ambrožicˇ1, Darko Zorman1,
Tjaša Furlan1, Mirta Koželj1, Matjaz Bunc1
1University Medical Centre Ljubljana, Ljubljana, Slovenia
Background: Balloon aortic valvuloplasty (BAV) is a palliative treatment for severe
aortic stenosis (AS). Restenosis after BAV can be resolved with another BAV or with
TAVI. We presented our experience with BAV and the results of RADAR-SLO study
where we evaluated the external beam radiation (EBRT) for prevention of restenosis.
Methods: Inclusion criteria for BAV were severe AS, increased operative risk, bridge to
surgical AVR/TAVI, urgent non-cardiac surgery. The severity of AS and LV function was
assessed with invasive and echocardiographic evaluation. In RADAR-SLO study we
randomized patients 2:1, the first group was treated with EBRT (total dose16Gy).
Results: 168 patients (age82.6y, LogEurosc22.1%) underwent BAV. After BAV we
observed an increase in AVA (0.59 to 0.70cm2, p0.05), a decrease in mean transval-
vular gradient (47.8 to 38mmHg, p0.05), without change of LV function (EF 53.3 to
54.9%, p0.75). The most common complications involved peripheral arterial accesses
(4.8%). BAV was performed in patients with CAD (N17) concomitant with PCI and in
patients with carcinoma (N7) that underwent major non-cardiac surgery. During 6
months follow up a restenosis of dilated valve occurred (restenosis rate 59%). Recurrence
of symptoms was resolved with another BAV (2 BAV N22, 3 BAV N3) or TAVI
(N22). During the follow up a trend towards better outcome was noted in the TAVI
patients. There was no impact of EBRT on restenosis and on survival rate (Fig.1).
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Conclusions: BAV can be utilized as a part of a complex therapy in severe AS in high
risk patients. EBRT has no impact on prevention of restenosis after BAV.
TCT-819
Effect of Transfemoral Aortic Valve Implantation on Plasma Brain
Natriuretic Peptide Levels and Its Predictive Value for 30-day and 1-year
survival
Karim El Chilali1, Thomas Konorza1, Fadi Al-Rashid1, Polykarpos Patsalis1,
Bjoern Plicht1, Daniel Wendt1, Matthias Thielmann1, Heinz Jakob1,
Raimund Erbel1, Philipp Kahlert1
1West German Heart Center, Essen, Germany
Background: To determine the effect of transfemoral aortic valve implantation (TF-
TAVI) on plasma BNP levels and to evaluate their predictive value for 30-day and
one-year survival.
Methods: Baseline BNP, peak BNP within 48 hours after TAVI and predischarge BNP
were obtained in 104 patients who underwent TF-TAVI with complete one-year
follow-up.
Results: BNP was elevated at baseline (298.2, IQR 145.8, 661.6 pg/ml) and showed an
acute increase after TF-TAVI (508.9, IQR 253.3, 868.6 pg/ml) followed by regression
towards baseline levels prior to discharge (327.2, IQR 159.2, 634.6 pg/ml), p 0.001.
Acute BNP increase (BNPpeak–baseline) is significantly higher in 30 days non-
survivors (277.1 IQR 252.1, 810 pg/ml) than in survivors (132.8 IQR10.1, 301 pg/ml),
p 0.028, and is found to be independent predictor of 30 days survival. Kaplan-Meier
(KM) survival analysis showed a reduced 30 days survival in patients with a BNPpeak–
baseline  248.9 pg/ml, p 0.002. For 1-year survival, predischarge BNP level (250.8,
IQR 152.9, 621.8 pg/ml in survivors vs. 591, IQR 354.5, 788 pg/ml in non survivors, p
0.003) and BNPdischarge-baseline(211.8 IQR 521.5, 91.1 pg/ml in survivors vs.
108.4 IQR 12.2, 272.6 pg/ml in non survivors, p0.002) are independent predictors. KM
analysis showed that 1-year survival is significantly lower in patients with a predischarge
BNP 327.2 and a BNPdischarge-baseline  38.3 than in those not fulfilling both
criteria, p 0.001.
Conclusions: BNP values are elevated in patients with severe, symptomatic aortic
stenosis presenting for TF-TAVI. They further increase acutely after procedure and
regress to baseline levels, usually prior to hospital-discharge. Acute, postprocedural BNP
increase is an independent predictor of reduced 30 days survival, while reduced 1-year
survival is predicted by higher predischarge BNP levels and failure of BNP to decline at
discharge below baseline BNP level.
TCT-820
Transcatheter Aortic Valve Implantation (TAVI) In Patients Unsuitable For A
Transfemoral Approach: A Comparison Between Trans-apical and
Trans-Axillary Approaches
Jason Leung Kwai Chan1, Raymond Cartier1, Xavier Freixa1, Ragui Ibrahim1,
Reda Ibrahim1, Yoan Lamarche1, Philippe Demers1, Raoul Bonan1, Anita Asgar1
1Montreal Heart Institute, Montreal, QC
Background: Transcatheter aortic valve implantation (TAVI) is an accepted alternative
in high-risk or inoperable patients with severe, symptomatic aortic stenosis. The
trans-femoral (TF) approach is most widely used however is limited in those with
peripheral vascular disease. The trans-apical (TA) and trans-axillary (TAx) approaches
have been described for such patients with limited data on outcomes. This study reports
our single center experience with both approaches and compares patient outcomes.
Methods: A retrospective study of patients undergoing TAVI from January 2010 to
December 2011. Procedural and clinical outcomes were defined according to the VARC
definitions.
Results: During the study period, 126 patients underwent TAVI at our hospital; 70 (55%)
patients were done by TF, 41 (33%) by TA and 15 (12%) by the TAx. Indications for TAx
or TA approach for TAVI in our institution were as follows: PVD in 34 patients (61%),
suboptimal size of femoral arteries (arterial diameter6 mm) in 23 (41%), AAA in 14
(25%), morbid obesity in 8 (14%). Procedural success, defined as implantation of the
device with a reduction in aortic valve gradient and without the need for conversion to
open heart surgery, was 93% (14/15) in TAx and 88% (36/41) in TA (p1.00). In TAx
group, two patients required retrieval of the devices and subsequent successful implan-
tation of another valve with the same approach. Valve embolization occurred in three TA
cases requiring conversion to conventional AVR.
Table 1: Baseline Characteristics, and Outcomes of TAVI Patients
(TAx and TA)
Baseline Characteristics TAx N (%) TA N (%) P value
Patients 15 41 -
Age (years), mean 	/ SD 81	/7.92 80	/5.99 0.68
Male 13 (87) 22 (54) 0.03
Diabetes 6 (40) 16 (39) 0.95
Morbid obesity, BMI 35 2 (13) 6 (15) 1.00
Peripheral vascular disease 8 (53) 27 (66) 0.39
Abdominal aortic aneurysm 6 (40) 8 (20) 0.12
Diameter of femoral arteries
6mm
6 (40) 17 (41) 0.92
Previous stroke/TIA 2 (13) 4 (10) 0.70
NYHA functional class III-IV 13 (87) 37 (90) 0.65
Outcomes
Successful procedure 14 (93) 36 (88) 1.00
In-hospital all-cause mortality 0 (0) 2 (5) 1.00
30-day all-cause mortality 0 (0) 5 (12) 0.31
Stroke/TIA 0 (0) 0 (0) -
Transfusions 4 (27) 20 (49) 0.23
Minor bleeding complication 3 (20) 7 (17) 1.00
Major bleeding complication 1 (7) 7 (17) 0.43
Life-threatening or disabling bleeding 0 (0) 5 (12) 0.31
Minor vascular complication 1 (7) 1 (2) 0.47
Major vascular complication 0 (0) 1 (2) 1.00
Conclusions: In this single center series the trans-axillary approach was associated with
a trend towards higher procedural success, lower all-cause mortality and fewer bleeding
complications than the trans-apical approach in patients with severe aortic stenosis. Larger
randomized controlled trials will be required to determine the true superiority of one
access site over the other.
TCT-821
Initial Experience With Transfemoral Implantation of the Prosthesis Edwards
Sapien XT Without Previous Valvuloplasty in Patients with Severe Aortic
Stenosis
Eulogio Garcia1, Patricia Martin1, Rosa Ana Hernandez1, Carlos Ramon Rodas1,
Jorge Enrique Sandoval Berrocal1, Ana Cuadrado1, Carlos Almerı´a1,
Carlos Macaya1
1Clinico San Carlos Hospital, Madrid, Spain
Background: Balloon valvuloplasty (BV) before transcatheter aortic implantation of the
prosthesis has been considered a mandatory step before valve implantation. However, BV
has been associated with complications such as atrioventricular block, aortic insufficiency
and stroke. We report 10 patients with severe aortic stenosis in whom direct transfemoral
implantation of the SAPIEN XT was performed.
Methods: From November 2011 to April 2012, 10 patients (33% of patients treated with
Edwards SAPIEN XT in that period were selected that met the following criteria:
moderate calcification, homogeneous distribution of calcium, symmetrical opening of the
valve and some degree of aortic insufficiency. The valve positioning was guided by TEE
in all cases.
Results: All patients had symptomatic aortic stenosis of a native valve and high risk
surgical; echocardiographic characteristics were: aortic annulus diameter ranged from 17
to 24 mm (determined by TEE). Six patients had the valve midly calcified, in four patients
the degree of calcification was moderate. All patients had symmetric opening of the
stenotic aortic valve. Mild aortic regurgitation was present in seven patients, moderate in
two and trivial in one. The native valve was crossed and the prosthetic aortic valve was
properly positioned in all cases and implanted in the correct position in all cases. No
patient underwent post-dilatation and only 1 patient had a mild periprosthetic regurgita-
tion. There were no adverse events (death, need for pacemaker, myocardial infarction or
stroke). At 30 days postprocedure all patients had significant clinical improvement.
Conclusions: Direct implantation of Edwards SAPIEN XT without prior balloon
valvuloplasty in selected cases is feasible and safe. The number of patients in whom this
technique is applicable and their impact on reducing complications has to be determined.
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